Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for ...
Vercel has released Next.js 16.2, featuring performance enhancements that make development startup 400% faster and rendering ...
A Bugcrowd researcher has unveiled ExploitBench, an independent benchmark of AI models for vulnerability exploitation ...
Whether it’s creating a strategy for current and future tech needs or deploying a new cybersecurity platform to protect company data, these IT consulting firms in and around Chicago are helping ...
A two-part adaptation of Stephen King's iconic novel of the same name. Seven children in Derry, Maine are terrorized by an eponymous being, only to face their own personal demons in the process. This ...
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...